FindTrial
Sign In

A clinical study of the Cyberknife and target therapy in the treatment of hilar lung carcinoma

A clinical study of the Cyberknife and target therapy in the treatment of hilar lung carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17013948
Enrollment
Unknown
Registered
2017-12-15
Start date
2017-12-16
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

1:target therapy+Cyberknife

Sponsors

Peking University Third Hospital, Department of Radiation Oncology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary or metastatic tumors of the eyes; 2. Oligo-metastases =6.

Exclusion criteria

Exclusion criteria: 1. Local lesions are not suitable for SRS; 2. Body poor constitution could not accept SRS; 3. EGFR drug resistant.

Design outcomes

Primary

MeasureTime frame
local control;—

Secondary

MeasureTime frame
PFS,OS;—

Countries

China

Contacts

Public ContactHongqing Zhuang

Peking University Third Hospital

yiduzhengmu@163.com+86 13051776232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026